Fed Governor Cook sues Trump over firing attempt
DURHAM, N.C. - Opus Genetics, Inc. (NASDAQ:IRD), a biotech firm specializing in ophthalmic gene therapies, has disclosed promising preliminary results from the first pediatric patient in a Phase 1/2 clinical trial of its investigational gene therapy, OPGx-LCA5. The therapy is aimed at treating LCA5-related inherited retinal disease (IRD), a condition that leads to early-onset vision loss. With a market capitalization of $38.5 million, InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 3.24, indicating robust short-term financial stability despite being in the development stage.
The company, which began dosing the first pediatric patients in February 2025, revealed that the initial patient, a 16-year-old, exhibited a meaningful improvement in visual function one month after receiving a single subretinal injection of OPGx-LCA5. Notably, no drug-related adverse events have been reported thus far.
The early data from the pediatric patient align with positive outcomes previously observed in adult participants. Tomas Aleman, M.D., the study's Principal Investigator, noted the patient's increased ability to perceive brightness, recognize letters, and navigate independently. George Magrath, M.D., CEO of Opus Genetics, expressed optimism about the potential of OPGx-LCA5 to restore significant vision in patients affected by LCA5.
The ongoing Phase 1/2 trial, which is enrolling both adult and pediatric patients, measures functional vision through various tests, including the Multi-Luminance Orientation and Mobility Test (MLoMT). Results from the three-patient pediatric cohort are expected in the third quarter of 2025. While the stock has experienced a challenging period, trading near its 52-week low of $0.80, InvestingPro subscribers have access to 8 additional key insights about the company's financial health and market position.
Opus Genetics recently engaged with the FDA in a Type D meeting to discuss the design of a potential registrational study for OPGx-LCA5, aiming to initiate a pivotal trial in the first quarter of 2026. The meeting provided constructive feedback on the proposed study design and statistical analysis plan.
LCA5 is a rare genetic disorder without any approved therapies to date. OPGx-LCA5 employs an adeno-associated virus vector (AAV8) to deliver a functional LCA5 gene to the retina. The investigational gene therapy is under evaluation at the University of Pennsylvania.
This report is based on a press release statement from Opus Genetics, Inc. The company's broader pipeline includes other gene therapies targeting various inherited retinal diseases and ophthalmic disorders. However, the press release also contains forward-looking statements, and the early data reported is preliminary and subject to validation in further trials. According to InvestingPro data, analysts maintain a strong buy consensus with price targets significantly above current levels, suggesting potential upside for investors willing to accept the risks of early-stage biotech investment. The company's next earnings report is scheduled for May 9, 2025, which could provide additional insights into the development pipeline's progress.
In other recent news, Opus Genetics reported an anticipated net loss of approximately $56.8 million for the year ending December 31, 2024. The company also estimated its cash and cash equivalents at about $30.3 million, though these figures are preliminary and subject to final adjustments. Opus Genetics successfully closed a $20 million public offering and a $1.5 million private placement, which are expected to fund corporate expenses and advance product development. Craig-Hallum Capital Group served as the sole underwriter for the public offering. The company is advancing its gene therapy programs, including OPGx-LCA5 and OPGx-BEST1, with the Phase 1/2 trial for OPGx-BEST1 scheduled for 2025. H.C. Wainwright reiterated a Buy rating for Opus Genetics, maintaining a price target of $8, citing optimism about the company's progress in its IRD pipeline. Additionally, Opus Genetics enhanced shareholder rights by amending its bylaws and filed a patent infringement lawsuit against Sandoz Inc. to protect its intellectual property. These developments reflect the company's ongoing efforts to align with shareholder interests and secure its commercial interests.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.